[CAS NO. 3094-09-5] Doxifluridine

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [3094-09-5]

Catalog

SLK-S2045

Brand

Selleck

CAS

3094-09-5

DESCRIPTION [3094-09-5]

Overview

MDL	MFCD00866530
Molecular Weight	246.19
Molecular Formula	C9H11FN2O5
SMILES	O[C@H]1[C@@H](O[C@H](C)[C@H]1O)N2C(=O)NC(=O)C(F)=C2

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	4.0619 mL	20.3095 mL	40.6190 mL
5 mM	0.8124 mL	4.0619 mL	8.1238 mL
10 mM	0.4062 mL	2.0310 mL	4.0619 mL
50 mM	0.0812 mL	0.4062 mL	0.8124 mL

Description

Doxifluridine (5'-DFUR, AMC 0101) is an oral prodrug that is converted to the cytotoxic agent 5-fluorouracil (5-FU).

In vitro

Doxifluridine suppresses tube formation of HUVEC and vascular endothelial growth factor production by FU-MMT-1 cells. Doxifluridine is converted to 5-FU and subsequently to FdUMP, and the results suggest that Doxifluridine exerts its cytotoxic effects through inhibition of TS and incorporation into RNA. Doxifluridine is a fluoropyrimidine derivative that is activated preferentially in malignant cells by thymidine phosphorylase to form 5-fluorouracil (5-FU). Doxifluridine is developed to improve the therapeutic index of 5-FU and to reduce toxicity, including the immunosuppressive, myelosuppressive, and cardiotoxic effects of 5-FU and other fluorinated pyrimidines.

In vivo

Metronomic Doxifluridine alone significantly suppresses tumor growth compared with the untreated (control) group, while metronomic Doxifluridine in combination with TNP-470 significantly inhibits tumor growth compared with each treatment alone in in FU-MMT-1 xenografts. Doxifluridine in combination with TNP-470 also leads to a significant reduction of intratumoral vascularity. Doxifluridine significantly inhibits the growth of KPL-4 tumors, reduces the tissue levels of IL-6, and alleviates body weight loss in nude mice bearing KPL-4 tumors. Doxifluridine results in a significant reduction in the activity of phenytoin p-hydroxylation in rats. Doxifluridine decreases the elimination rate constant and the total clearance in rats.

References

[1] Naganuma Y, et al. Cancer Sci,?011, 102(8), 1545-1552.
[2] Berne M, et al. Cancer Invest,?988, 6(4), 377-383.
[3] Baek IH, et al. Eur J Drug Metab Pharmacokinet,?013, 38(4), 295-299.
[4] Yamamoto S, et al. Gan To Kagaku Ryoho,?999, 26(10), 1443-1448.
[5] Konishi H, et al. J Pharm Pharmacol,?003, 55(1), 143-149.

Synonyms

Uridine, 5′-deoxy-5-fluoro-

5′-Deoxy-5-fluorouridine

Ro 21-9738

Doxifluridine

5-Fluoro-5′-deoxyuridine

5-Fluorodesoxyuridine

5′-DFUR

Furtulon

5′-dFUrd

Flutron

Fulturon